SARM and GLP-1 Combination for Lean Mass Preservation in Weight Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing weight loss drugs, such as GLP-1 RAs and SGLT-2 inhibitors, cause non-selective loss of both fat and lean body mass, leading to muscle loss, muscle weakness, and compromised physical function, with potential rebound weight gain upon drug discontinuation.
Innovation Solution
A composition comprising a selective androgen receptor modulator (SARM) compound co-administered with incretin agonist or antagonist containing drugs to mitigate adverse effects on body composition and physical function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If weight loss drugs (GLP-1 RAs or SGLT-2 inhibitors) are used to reduce body weight and fat mass, then weight loss and fat mass reduction are achieved, but lean body mass is lost and muscle strength decreases
Solution Approach 1:
The invention segments the weight loss effect from the muscle preservation effect by combining two different drug mechanisms: GLP-1 RAs for fat loss and SARMs for muscle preservation. This allows independent optimization of fat reduction while preventing muscle loss.
Solution Approach 2:
The invention creates a composite pharmaceutical regimen combining GLP-1 RAs and SARMs, where each component performs a distinct function: GLP-1 RAs target adipose tissue metabolism while SARMs selectively bind to androgen receptors in muscle tissue to prevent catabolism.
2Quantity of substance
If weight loss drugs are used to achieve weight loss, then body weight is reduced, but physical function is compromised
Solution Approach 1:
The invention separates the effects on body weight and physical function by using GLP-1 RAs to reduce body weight through fat loss while SARMs independently maintain physical function through muscle preservation and strength enhancement.
Solution Approach 2:
SARMs act as an intermediary substance that mediates between weight loss and physical function maintenance, selectively preserving muscle tissue and strength while allowing fat loss to occur through the GLP-1 RA mechanism.
3Quantity of substance
If weight loss drugs are used to reduce body weight, then weight loss is achieved, but rebound weight gain occurs upon drug discontinuation
Solution Approach 1:
The invention applies preliminary action by using SARMs to build and preserve muscle mass before and during weight loss, creating a metabolic foundation that prevents rebound weight gain when GLP-1 RAs are discontinued.
Solution Approach 2:
The invention changes the body composition parameters by maintaining higher lean body mass percentage through SARMs while reducing fat mass through GLP-1 RAs, creating a stable metabolic profile that resists rebound effects.
4Quantity of substance
If non-selective weight loss occurs, then both fat and lean mass are lost, but body composition quality deteriorates
Solution Approach 1:
The invention applies local quality by making the weight loss effect selective: GLP-1 RAs specifically target adipose tissue for metabolism while SARMs selectively protect muscle tissue, achieving weight loss with improved body composition quality.
Solution Approach 2:
The invention changes body composition parameters by reducing fat mass percentage while maintaining or increasing lean body mass percentage, transforming the quality of weight loss from non-selective to selective fat loss.
Data Source
AI summary
The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.